SCHEMBL16093364

SCHEMBL16093364

CCc1cnn(CC2CC2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
PI4KA P42356 1/20 0.38
PIK3CG P48736 1/20 0.38
PI4KB Q9UBF8 1/20 0.38
PARG Q86W56 1/20 0.38
HDAC1 Q13547 2/20 0.37
HDAC2 Q92769 2/20 0.37
CREBBP Q92793 1/20 0.37
KDM5B Q9UGL1 1/20 0.36
CSF1R P07333 1/20 0.36
TSHR P16473 1/20 0.35
TLR7 Q9NYK1 2/20 0.34
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
KDM1A O60341 1/20 0.33
FEN1 P39748 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
CRHR1 P34998 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25727726 0.93 NPC1 (0.36) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL20696931 0.89 JAK2 (0.43) PIK3CDPIK3CAPARGCSF1RKDM1A
SCHEMBL30628841 0.85 PIK3CD (0.40) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL29541577 0.84 TSHR (0.40) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL21245975 0.82 SCD (0.42) PIK3CAPARGTLR7JAK2JAK1
SCHEMBL25118790 0.82 PIK3CD (0.37) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL15721483 0.81 GABRA1 (0.46) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL30240771 0.81 PIK3CD (0.38) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL24828309 0.81 PIK3CD (0.38) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL24828649 0.81 PIK3CD (0.38) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787780-B2 Quaternary indazole glucocorticoid receptor antagonists CORCEPT THERAPEUTICS INCORPORATED (US) 2023-10-17 US disclosed
US-20230032612-A1 QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS CORCEPT THERAPEUTICS INCORPORATED 2023-02-02 US disclosed
EP-2606031-B1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS INC (US) 2017-09-27 EP disclosed
US-8841455-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors ARRAY BIOPHARMA INC. (US) 2014-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787780-B2 Quaternary indazole glucocorticoid receptor antagonists NR3C1, NR3C2, MC2R PIK3CD 1370/4885PIK3CA 1491/4885PIK3CB 1856/4885
US-20230032612-A1 QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS NR3C1, NR3C2, MC2R PIK3CD 1370/4885PIK3CA 1491/4885PIK3CB 1856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.